Aldeyra Therapeutics Inc. (NASDAQ: ALDX)
$3.97
+0.1050 ( +2.72% ) 218.7K
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Market Data
Open
$3.97
Previous close
$3.86
Volume
218.7K
Market cap
$235.28M
Day range
$3.75 - $3.97
52 week range
$1.42 - $8.38
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 65 | Apr 25, 2024 |
def | Proxies and info statements | 7 | Apr 22, 2024 |
ars | Annual reports | 1 | Apr 22, 2024 |
4/a | Other | 1 | Apr 17, 2024 |
4/a | Other | 1 | Apr 17, 2024 |
4 | Insider transactions | 1 | Apr 08, 2024 |
4 | Insider transactions | 1 | Apr 03, 2024 |
8-k | 8K-related | 15 | Mar 28, 2024 |
4 | Insider transactions | 1 | Mar 12, 2024 |
4 | Insider transactions | 1 | Mar 12, 2024 |